The Treatment of Narcolepsy-Cataplexy with Nocturnal Gamma-Hydroxybutyrate

ROGER BROUGHTON AND MORTIMER MAMELAK

SUMMARY: Sixteen patients with narcolepsy and cataplexy were treated with gamma-hydroxybutyrate (GHB) given at night and tailored to achieve as continuous a night's sleep as possible. The dosage usually consisted of 1.5-2.25 gm orally at bedtime and then one or two further 1.0-1.5 gm doses with awakenings during the night, and totaled about 50 mg/kg. Apart from one patient who took only the bedtime dose, the subjective quality of night sleep improved in all patients and the number of irresistible daytime attacks of sleep and cataplexy substantially diminished. Some residual daytime drowsiness remained and this usually responded well to low doses of methylphenidate. Improvement has been maintained for up to 20 months without the development of tolerance. Two patients experienced adverse side effects necessitating withdrawal of GHB treatment, but no serious toxic effects have occurred.

INTRODUCTION

The prevalence of narcolepsy has been shown in epidemiological studies to be about 0.1% (Roth, 1962; Dement et al., 1973). Therefore it is more frequent than a number of much better known chronic neurological conditions, such as multiple sclerosis. Moreover, as it generally begins in young adulthood and remains for the patients' lifetime, and as it has marked detrimental effects involving employment, education, recreation, interpersonal relations, driving, accidents in general and other parameters of everyday life (Broughton and Ghanem, 1976), the condition can be truly debilitating. The investigation of narcolepsy by modern polysomnographic techniques has shown that of the classical so-called 'tetrad' of Daly and Yoss (1960), the auxiliary symptoms (i.e. those other than sleep attacks) of cataplexy, sleep paralysis, and vivid hypnagogic hallucinations are all based upon abnormal rapid-eye-movement (REM) sleep mechanisms, and that the sleep attacks of patients with narcolepsy-cataplexy begin in REM sleep in 50-100% of attacks (Broughton, 1971; Zarcone, 1973), depending upon the author. These findings have led to the addition of drugs which suppress REM sleep, i.e. tricyclic antidepressants (imipramine, chlorimipramine, and desipramine) or less frequently MAO inhibitors (phenelzine) to traditional stimulant medication, usually methylphenidate. The antidepressants have been largely effective in reducing the auxiliary symptoms of cataplexy, sleep paralysis and hypnagogic hallucinations, whereas methylphenidate has been most useful for the sleep attacks and for the more or less continuous daytime drowsiness.

From the Division of Neurology, Ottawa General Hospital and University of Ottawa, and the Department of Psychiatry, Sunnybrook Medical Centre and University of Toronto, Canada.

Reprints requests to: Dr. Broughton, Department of Medicine (Neurology), Ottawa General Hospital, Ottawa, Canada, K1N 5C8.
presented by these patients (Zarcone, 1973). Despite these therapeutic improvements over stimulants alone, the treatment of narcolepsy still remains unsatisfactory. In many patients control of symptoms is far from complete. Others show undesirable side effects discussed later.

This situation led us to use a somewhat different therapeutic strategy. Rather than concentrating upon suppressing the daytime symptoms, we decided to attempt to improve their night-time sleep, which is characterized by early or direct entry into REM sleep (Rechtschaffen et al., 1963), much sleep fragmentation with particular inability to sustain periods of REM sleep (Montplaisir, 1976), and by other features, in the hope that daytime pressure for sleep-related symptoms would be reduced. There were at least two reasons for suggesting that disturbed nocturnal sleep might be central to the physiopathogenesis of narcolepsy with cataplexy. First, prolonged periods of sleep deprivation or of irregular sleep precede the onset of major symptoms of the disease in 50–75% of patients (Mitchell and Dement, 1968; Broughton and Ghanem, 1976) with idiopathic narcolepsy. Secondly, narcoleptics are known to be very vulnerable to the effects of shift work, and therefore to alteration in their circadian sleep-wakefulness rhythms. Such disturbances regularly aggravate their symptoms (Broughton, 1971).

We chose the sodium salt of gamma-hydroxybutyrate (GHB) (Laborit, 1964; Muzard and Laborit, 1977; Snead, 1977) in our attempt to “normalize” the nocturnal sleep patterns of patients with narcolepsy and cataplexy. This short chain fatty acid is a normal constituent of the human nervous system (Doherty and Roth, 1976). It possesses definite hypnotic properties. But in distinction to the commonly used synthetic hypnotics, it promotes sleep which more closely approximates that of normal sleep than do other hypnotics, since it does not inhibit either REM or NREM sleep (Jouvet et al., 1961; Matsuzaki et al., 1964; Mamakel et al., 1977; Muzard and Laborit, 1977). GHB also has an additional possible advantage over the synthetic hypnotics in that animal studies had failed to demonstrate the development of tolerance to its hypnotic effects with prolonged use (Vickers, 1969). To date we have treated 16 patients with nocturnal GHB. Preliminary results in our first four patients have already been reported (Broughton and Mamakel, 1976).

PATIENTS AND METHODS

The sixteen patients, 8 men and 8 women, ranged in age from 21-58 years (Mean 41.8, s.d. 13.6; Table 1). All had histories of diurnal drowsiness, irresistible sleep attacks, and cataplexy. The other main symptoms of the disease were also present in individual patients to varying degrees. In four patients, the symptoms had been particularly debilitating in spite of treatment with the usual combination of methylphenidate and tricyclic antidepressant drugs. The entire protocol and the investigative nature of the study were carefully explained to each patient and consent forms were signed. In all patients, a sleep onset REM period was observed during at least one daytime polysomnographic recording. Before starting treatment with GHB, all previous drug treatment for narcolepsy was discontinued for at least 14 days. A history and physical were performed and the following laboratory tests completed: hemogram, liver survey, renal survey, chest x-ray, EEG and ECG. Each patient was also given a psychological examination and the Minnesota Multiphasic Personality Inventory.

Polysomnographic assessment of sleep-waking patterns was done for at least 48 continuous hours in the baseline state and then at regular intervals while on GHB. In the Ottawa patients (N = 9) recordings were performed without hospitalization using a portable 4-channel apparatus which permitted the monitoring of patients at their habitual activity levels in the normal home or work environment. In the Toronto studies, patients (N = 7) were hospitalized during the recording periods and the usual polysomnographic techniques were employed. None of the patients had histories of loud snoring or of the peculiar guttural inspiratory snoring which characterizes sleep apnea.

Moreover, this symptom was formally excluded by respiratory monitoring (nasal thermistor and abdominal belt transducer) in Toronto studies, where sufficient recording channels made this possible. The Stanford Sleepiness Scale (Hodges et al., 1973), which is a self-assessed 1 to 7 scale of alertness, was filled in every 30 minutes over at least 3 consecutive days during wakefulness in the pre-GHB baseline period, and during reassessments while on the drug.

Treatment with GHB was started once the initial baseline data was gathered. The treatment schedule was tailored to achieve as continuous a night’s sleep as possible. The patient’s body weight and his polysomnographic response to GHB were used as guides. Since each sleep inducing oral dose of GHB lasts only two or three hours (Mamakel et al., 1977) — indeed the substance is only detectable in blood that long (Helrich et al., 1964) — and because our aim was to maximize the duration of sleep produced by the drug while minimizing its anaesthetic effects, multiple doses were used. The usual initial dose was 1.5-2.25 gm (10-15 ml) hs, followed by further multiple 1.0-1.5 gm doses during the night with each major reawakening, if at least 2.5 hours had passed since the previous dose. Usually only 2 or 3 doses per night were necessary. Each dose was about 30 mg/kg, but the total quantity of GHB given each night ranged from 3.75 to 6.25 gms, corresponding to approximately 50 mg/kg.

After seven to ten nights on GHB, the 48 hour polysomnographic recording was repeated with the patient continuing to use the drug according to the optimal dose schedule previously established. Major reassessments were again performed after at least one month, six months and 12 months on GHB. On each of these occasions, the clinical effects of the treatment were assessed, the blood and urine studies, chest x-ray and ECG were repeated, and any adverse reactions to the drug noted and investigated.

GHB was obtained from Laboratoire Egic in France, who market this drug in syrup form under the trade name Narcolepsy and Gamma-Hydroxybutyrate.
TABLE 1.

Patients' Symptoms, Previous Treatment and Response to Nocturnal Gamma Hydroxy Butyrate

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age</th>
<th>Sex</th>
<th>Major Symptoms</th>
<th>Duration of Illness</th>
<th>Previous Medication</th>
<th>Usual GHB Dosage gm/night</th>
<th>Response</th>
<th>Toxicity</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>21</td>
<td>F</td>
<td>N,SP,HH rare C</td>
<td>6 years</td>
<td>diazepam hs</td>
<td>3.0</td>
<td>+++</td>
<td>none</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>22</td>
<td>M</td>
<td>N,C,SP,HH</td>
<td>4 years</td>
<td>diazepam sed*</td>
<td>3.75</td>
<td>+</td>
<td>none</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>23</td>
<td>F</td>
<td>N,C,SP,HH</td>
<td>3 years</td>
<td>none</td>
<td>3.75</td>
<td>+++</td>
<td>none</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>25</td>
<td>F</td>
<td>N,SP</td>
<td>5 years</td>
<td>benzedrine</td>
<td>2.25</td>
<td>0</td>
<td>none</td>
<td>Took only hs dose</td>
</tr>
<tr>
<td>5</td>
<td>32</td>
<td>F</td>
<td>N,C,SP,HH</td>
<td>14 years</td>
<td>dexedrine</td>
<td>5.25</td>
<td>+++</td>
<td>none</td>
<td>Sister of pat. 4</td>
</tr>
<tr>
<td>6</td>
<td>38</td>
<td>F</td>
<td>N,C,SP,HH</td>
<td>15 years</td>
<td>dexedrine methylphenidate chlorimipramine</td>
<td>3.75</td>
<td>+++</td>
<td>none</td>
<td>Old gastrectomy</td>
</tr>
<tr>
<td>7</td>
<td>40</td>
<td>M</td>
<td>N,C,SP,HH</td>
<td>28 years</td>
<td>dexedrine methylphenidate imipramine chlorimipramine phenelzine</td>
<td>4.50</td>
<td>+++</td>
<td>none</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>43</td>
<td>F</td>
<td>N,C,SP,HH</td>
<td>13 years</td>
<td>dexedrine methylphenidate imipramine chlorimipramine phenelzine phenytoin carbamazepine</td>
<td>4.50</td>
<td>++</td>
<td>abdominal pain, muscle weakness</td>
<td>No evidence for epilepsy</td>
</tr>
<tr>
<td>9</td>
<td>45</td>
<td>F</td>
<td>N,C,SP</td>
<td>23 years</td>
<td>dexedrine</td>
<td>6.25</td>
<td>+</td>
<td>none</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>45</td>
<td>M</td>
<td>N,C,SP,HH</td>
<td>3 years</td>
<td>methylphenidate</td>
<td>4.50</td>
<td>+++</td>
<td>temporary muscle weakness</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>52</td>
<td>M</td>
<td>N,C,SP</td>
<td>14 years</td>
<td>desoxyn</td>
<td>3.75</td>
<td>+++</td>
<td>none</td>
<td>Impotence on previous R</td>
</tr>
<tr>
<td>12</td>
<td>55</td>
<td>M</td>
<td>N,C</td>
<td>30 years</td>
<td>methylphenidate</td>
<td>3.75</td>
<td>+++</td>
<td>none</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>56</td>
<td>M</td>
<td>N,C,SP</td>
<td>31 years</td>
<td>methylphenidate</td>
<td>3.75</td>
<td>+++</td>
<td>dysthesiae left hand</td>
<td>Post-traumatic epilepsy</td>
</tr>
<tr>
<td>14</td>
<td>57</td>
<td>M</td>
<td>N,C</td>
<td>43 years</td>
<td>ephedrine</td>
<td>4.50</td>
<td>+++</td>
<td>none</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>57</td>
<td>M</td>
<td>N,C,SP,HH</td>
<td>33 years</td>
<td>dexedrine</td>
<td>5.25</td>
<td>+++</td>
<td>none</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>57</td>
<td>F</td>
<td>N,C,SP,HH</td>
<td>37 years</td>
<td>dexedrine methylphenidate imipramine chlorimipramine</td>
<td>3.75</td>
<td>+++</td>
<td>none</td>
<td></td>
</tr>
</tbody>
</table>

0 = no effect; +/− = 0-20% improvement; + = 20-40% improvement
++ = 40-70% improvement; +++ = over 75% reduction of symptoms from baseline

N = irrisistible sleep attacks; C = cataplexy; SP = sleep paralysis; HH = vivid hypnagogic hallucinations

name "GammaOH". We found it best to dilute the syrup in milk or juice, in order to reduce the gastrointestinal upset caused in some patients when the drug was given in undiluted form. Dilution also retarded GHB's rate of absorption somewhat, so that sleep induction was experienced as gradual and more normal.

RESULTS

We wish to report our clinical observations here. The polysomnographic and Stanford Sleep Scale data and our psychological findings are still being analyzed and will be presented in a future publication. The patient and clinical results are summarized in Table 1.

CLINICAL RESPONSE

The ameliorating effects of GHB on the major daytime symptoms of narcolepsy appeared gradually. By comparison, the subjective quality of night-time sleep improved very rapidly. Over the first 2 to 5 nights, nocturnal sleep became less restless and nightmares, hallucinations, and attacks of sleep paralysis vanished. Some episodes of intense awakenings at about 2-3 hours after taking the initial doses were encountered. These appeared to represent a drug-related rebound phenomenon. Although dreaming continued, it lost its frightening qualities. All patients found it easier to stay awake during the day and noted that after a number of weeks, the irresistible pressure for diurnal sleep and the attacks of cataplexy virtually disappeared. When cataplexy did occur, the attacks were
Minor side effects of GHB have been
seen for the first few days in a number
of patients which consisted of a “thick
head”, ocular discomfort, and other
apparent hangover effects, but these
were rare after one week. Impotence or
reduced libido has never been
encountered. We decided to discontinue
the drug in two patients. One
(patient No. 8) complained of non-
specific abdominal pain while using
GHB plus muscular weakness in the
morning, to the point where she found
it difficult to initiate movement.
Both of these symptoms disappeared
when the drug was stopped. A second
patient (No. 13), a male with a post-
traumatic narcolepsy and cataplexy,
experienced disturbing left arm
dysthesiae. He had previously had
similar symptoms after the initial head
injury. A third patient (No. 10)
complained of muscular weakness in
the morning, also limited to his left
arm. This man had suffered a neck
injury a few weeks before starting
GHB and his left arm was weak
following the event. It had gradually
been recovering, but the weakness
recurred when he started using the
drug. Because his narcolepsy
improved so dramatically on GHB, we
continued to use the drug in spite of
the effect on his arm and the weakness
gradually disappeared over a few
weeks.

Several patients have also mentioned
that GHB caused urinary urgency.
On one occasion, enuresis occurred in
a patient about an hour after the drug
had been given. On the whole,
hardly, however, urgency has not been a
serious problem and our patients
report that they void no more
frequently during the night on GHB
than they did before starting the drug.
Another complaint from a number of
patients was that GHB produced a
dream-like confusional state which
could be unpleasant and frightening.
This happened when the drug was
taken before they were ready for sleep,
or when they fought against its sleep
promoting actions. This phenomenon
rare if patients cooperate with the
drug’s hypnotic effects and use it at the
minimal dose required for sleep
induction and maintenance. No other
side-effects were encountered and, in
sum, most patients felt they had fewer
side-effects and substantially better
relief from symptoms on GHB than on
any previous medication.

**DISCUSSION**

The salient finding in this study was
the marked clinical improvement
produced by nocturnal GHB in
patients with narcolepsy-cataplexy.
This action was coupled with a paucity
of adverse clinical or laboratory
findings. When GHB was used at
night, and supplemented with small
doses of methylphenidate during
the day, all the major symptoms of
narcolepsy were markedly reduced.
The project has involved detailed
study of a limited number of patients
over substantial periods of time. It is
not a double-blind controlled design.
But, the therapeutic effects on patients
previously uncontrolled by the more
traditional drug regimens and the
rapid deterioration in those who
discontinued the use of the drug on
their own for several nights leave little
doubt about the compound’s effective-
ness.

The use of GHB for the treatment of
this disease has a number of clear
advantages over more conventional
therapies. As mentioned, the latter
usually use substantial doses of
stimulants such as methylphenidate or
d-amphetamine, alone, or in combina-
tion with tricyclic antidepressants
such as imipramine or chlorimipramine.
The stimulants, however, cause
irritability and anxiety in many
patients and more serious side effects
in others. One of our patients
previously had had a gastrectomy for
ulcers attributed to stimulant medica-
tion. The antidepressant drugs, on the
other hand, may cause dry mouth,
sweating, and impotence in males
(Zarcone, 1973; Dement et al., 1976).
The stimulant-antidepressant combin-
ation does not consolidate sleep, and
in fact may even further disrupt it.
Moreover, tolerance develops in time
both to the level of stimulants
generally employed and to antidepres-
sants so that after a number of months,
many patients complain that their
symptoms are again every bit as
troublesome as they were to begin
with. None of these problems occur
with GHB. Nocturnal sleep was restful

**SIDE EFFECTS**

There have been very few adverse
clinical effects with this treatment and
no abnormal laboratory findings.
and sustained and patients awoke alert and well rested. There were few side effects and, specifically, no impotence or reduced libido. Tolerance to the drug’s actions did not develop, nor did it develop to the relatively small doses of methylphenidate taken during the day, when taken in combination with nocturnal GHB.

Some of the therapeutic and side-effects of GHB may be related to its influence on motor mechanisms. It is known to inhibit muscle tone (Vickers, 1969) and to block the H-reflex response (Uspenskii, 1965; Muzard and Laborit, 1977). In narcoleptics, as well as in normals, the H-reflex response can be abolished by GHB and remains somewhat attenuated for some time after the patient awakens (Mamelak, Bowden and Caruso, unpublished observations). The latter may be due to residual effects of small quantities of unmetabolized drug. This effect may account for the weakness experienced by two of our patients upon arising in the morning. The sustained hypotonia throughout sleep may be as important as any effect on sleep patterns in the subjective feeling of having had a deep refreshing night’s sleep. As far as the urinary urgency is concerned, this has been noted by some patients even if they empty their bladders before bedtime, but it has not proved to be a treatment problem. It is intriguing to speculate, however, that the combination of profound sleep and enuresis observed in childhood might be related to a higher brain GHB concentration present in the early years of life.

GHB’s mechanisms of action in the treatment of the major symptoms of narcolepsy remains uncertain. It has been known for many years that hypnotic drugs can be helpful for at least some narcoleptic patients (Daniels, 1934; Zarcone, 1973). Recent studies have shown that narcoleptics do not sleep more in the 24-hour period than normal individuals (Hishikawa et al., 1976). Thus, consolidating the fragmented sleep of these patients into a seven or eight hour period by means of hypnotic drugs should theoretically decrease the need for daytime sleep. Perhaps this is how ordinary hypnotics benefit these patients. But, it must be noted that some of our narcoleptic patients slept reasonably soundly at night and that in these patients nocturnal sleep in fact became more fragmented after starting GHB, because they had to wake up for the second dose. If they failed to take it their symptoms recurred. Furthermore, a preliminary review of our polysomnographic data indicates that GHB did not substantially increase the overall duration of sleep in the eight hour night-time period. GHB, then, likely has more specific actions on sleep mechanisms than simply increasing the duration of nocturnal sleep or its gross continuity. As yet, basic neurochemical studies offer few real insights into the drug’s mechanism of action, although it has been shown that GHB may be derived from GABA (Roth and Giarman, 1969), and may act as a GABA agonist (Roth et al., 1977) and that it alters dopamine (Roth and Suhr, 1970), serotonin (Spono et al, 1970), and acetylcholine (de la Mora et al., 1970) metabolism. The last three, at least, have been implicated in sleep control mechanisms (Jasper and Koyama, 1969; Jouvet, 1969; Cordeau, 1970; Morgane and Stern, 1972).

Whatever its precise mode of action, this essentially non-toxic constituent of the normal brain does appear to have important clinical therapeutic effects even in otherwise refractory cases of narcolepsy. Moreover, its effectiveness, when given in the night-time period, adds strong support for the postulated importance of the quality of night sleep in the genesis of daytime sleep attacks and cataplexy. It gives promise that GHB itself or similar substances (we have also used gamma-butyrlactone successfully) may lead to substantial improvement in the control of this debilitating neurological disease. The main disadvantage at present is its relatively short duration of action. It is hoped that this might be extended by use of slow release capsules or another approach in order to produce a sustained 7-8 hour overnight effect.

ACKNOWLEDGEMENTS

We thank Lavoratore Egge, Paris for supplying the gamma-hydroxybutyrate and the Health Protection Branch, Health and Welfare Canada (Dr. T. Da Silva) for giving clearance to import the substance for the clinical trial. We also thank Tom Healey, Jagdish Maru, Olga Stokan, Vicky Caruso and Keith Stewart for their technical assistance with this project. The project has been supported by the Medical Research Council of Canada.

REFERENCES


